Key Takeaways on Biomarker Utilization in Metastatic NSCLC

This discussion explores key insights from a retrospective study evaluating biomarker testing practices in non–small cell lung cancer (NSCLC) and how these findings inform current and future care. Panelists will share perspectives on interpreting the study results and how they align with real-world clinical experience. The conversation will examine current approaches to biomarker testing, including whether adoption of comprehensive testing has meaningfully increased since the study’s publication in 2022. Ongoing barriers to broad biomarker utilization in metastatic NSCLC—such as workflow challenges, tissue limitations, turnaround time, and access issues—will also be addressed. Finally, the discussion will look ahead to how the growing role of antibody–drug conjugates (ADCs) may further expand the need for comprehensive and timely biomarker testing, potentially reshaping diagnostic workflows to better support precision oncology.